<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136237">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992380</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A03</org_study_id>
    <nct_id>NCT01992380</nct_id>
  </id_info>
  <brief_title>A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects</brief_title>
  <official_title>Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test if two 18F-AV-1451 PET scans up to 4 weeks apart in healthy volunteers,
      MCI and AD subjects provide the same results.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Test-Retest Reproducibility</measure>
    <time_frame>130 minutes post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate test-retest reproducibility of 18F-AV-1451 for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellum, will be evaluated using intraclass correlation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteer Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two i.v. bolus injections of approximately 370 Megabecquerels (MBq) of 18F-AV-1451 up to four weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two i.v. bolus injections of approximately 370 MBq of 18F-AV-1451 up to four weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probable AD Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two i.v. bolus injections of approximately 370 MBq of 18F-AV-1451 up to four weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-1451</intervention_name>
    <arm_group_label>Healthy Volunteer Subjects</arm_group_label>
    <arm_group_label>MCI subjects</arm_group_label>
    <arm_group_label>Probable AD Subjects</arm_group_label>
    <other_name>[F18]T807</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers

               -  Male or female subjects ≥ 50 years of age

               -  Mini-mental state examination (MMSE) ≥ 29

          -  MCI Subjects

               -  Male or female subjects ≥ 50 years of age

               -  MMSE ≥ 24

               -  Have MCI consistent with National Institute on Aging-Alzheimer's Association
                  (NIA-AA) working group's diagnostic guidelines for AD

               -  Have a study partner that can report on subject's activities of daily living

          -  Probable AD Subjects

               -  Male or female subjects ≥ 50 years of age

               -  MMSE &gt; 10

               -  Meet clinical criteria for probable AD based on the NIA-AA working group's
                  diagnostic guidelines for AD

               -  Have a study partner that can report on subject's activities of daily living

        Exclusion Criteria:

          -  Current clinically significant psychiatric disease

          -  Evidence of structural brain abnormalities

          -  Evidence of dementing illness other than AD

          -  Current clinically significant cardiovascular disease or ECG abnormalities, or
             additional risk factors for Torsades de Pointes

          -  Current clinically significant infectious disease, endocrine or metabolic disease,
             pulmonary, renal or hepatic impairment, or cancer

          -  History of alcohol or substance abuse or dependence

          -  Females of childbearing potential who are not surgically sterile, not refraining from
             sexual activity or not using reliable methods of contraception

          -  Have received or participated in a trial with investigational medications in the past
             30 days

          -  have had a non-study related radiopharmaceutical imaging or treatment procedure
             within 7 days prior to the study imaging session.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
